Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 ( JAK2 ) V617F and KIT proto‐oncogene, receptor tyrosine kinase ( KIT ) D816V mutations-Reference-Cited by-同舟云学术

Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 ( JAK2 ) V617F and KIT proto‐oncogene, receptor tyrosine kinase ( KIT ) D816V mutations

Published:2021-06 Issue:2 Volume:194 Page:344-354
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Naumann Nicole¹^ORCID,Lübke Johannes¹,Shomali William²^ORCID,Reiter Lukas¹,Horny Hans‐Peter³,Jawhar Mohamad¹,Dangelo Vito¹,Fabarius Alice¹,Metzgeroth Georgia¹,Kreil Sebastian¹,Sotlar Karl⁴,Oni Claire⁵,Harrison Claire⁵,Hofmann Wolf‐Karsten¹,Cross Nicholas C. P.⁶⁷,Valent Peter⁸,Radia Deepti⁵^ORCID,Gotlib Jason²,Reiter Andreas¹,Schwaab Juliana¹^ORCID

Affiliation:

1. Haematology and Oncology Medical Faculty Mannheim Heidelberg University Mannheim Germany

2. Division of Hematology Stanford Cancer Institute/Stanford University School of Medicine Stanford CA USA

3. Institute of Pathology Ludwig‐Maximilian‐University Munich Germany

4. Institute of Pathology University Hospital SalzburgParacelsus Medical University Salzburg Austria

5. Department of Haematology Guy’s and St Thomas’ NHS Foundation Trust LondonUK

6. Wessex Regional Genetics Laboratory Salisbury UK

7. School of Medicine University of Southampton Southampton UK

8. Department of Internal Medicine I Division of Haematology and Ludwig Boltzmann Institute for Haematology and Oncology Medical University of Vienna Vienna Austria

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17567

Reference40 articles.

1. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

2. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients

3. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

4. Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model

5. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR;Annals of Hematology;2024-07-24

2. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM;Blood Advances;2024-06-05

3. Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis;Cancers;2024-01-30

4. KIT Mutations and Other Genetic Defects in Mastocytosis;Immunology and Allergy Clinics of North America;2023-11

5. New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy;Annual Review of Pathology: Mechanisms of Disease;2023-01-24